Abstract
Aim: The aim of this paper is to summarize the experience and results of deep vein thrombosis prevention after standardized abdominal tumor resection and lymph node dissection, and to investigate standardized treatment methods for postoperative thrombosis prevention. Methods: We performed a retrospective analysis of the clinical data for 548 patients who were given low molecular weight heparin, low molecular weight dextran, or IV salvia to prevent thrombosis development between January 2007 and April 2010 after standardized abdominal tumor resection and lymph node dissection. Patients were divided into the following three groups based on the treatment period and treatment schedule: group 1 included 163 patients who had been treated between January 2007 and March 2008 and received a 7-day course of daily low molecular weight dextran (500 mL) and salvia injection (0.2 g) postoperatively; group 2 included 149 patients who had been treated between April 2008 and March 2009 and received a 7-day course of daily low molecular weight dextran (500 mL), salvia injection (0.2 g), and low molecular weight heparin (40 mg) postoperatively; group 3 included 236 patients who had been treated between April 2009 and April 2010 and postoperatively received a 7-day course of daily low molecular weight dextran (500 mL) and salvia injection (0.2 g), and on postoperative day 3 were started on an additional 7-day course of daily low molecular weight heparin (40 mg). Then, we performed comparative analysis of the treatment efficacy and concomitant symptoms. Results: In group 1, 64 of the 163 cases (39.3%) were positive for D-dimer, and 15 (9.2%) cases were positive for DVT based on Doppler imaging of the lower extremities. In group 2, 38 cases (25.5%) were positive for D-dimer and 3 cases (2.0%) for DVT. In group 3, 62 cases (26.3%) were positive for D-dimer and 6 cases (2.5%) for DVT. In general, the administration of low molecular weight heparin for anticoagulation in groups 2 and 3 led to significant reduction of thromboses when compared to group 1. However, altering the initiation day of low molecular weight heparin administration between groups 2 and 3 did not result in significant differences in the rate of thrombosis formation. Through clinical observation, early administration of low molecular weight heparin may increase adverse effects. Conclusion: We have demonstrated the superior efficacy of postoperative administration of low molecular weight dextran and IV salvia with additional subcutaneous injection of low molecular weight heparin on postoperative day 3 to prevent DVT development after radical resection of abdominal tumors.
Highlights
Deep venous thrombosis (DVT) is a serious complication that occurs after major abdominal surgeries
We have demonstrated the superior efficacy of postoperative administration of low molecular weight dextran and IV salvia with additional subcutaneous injection of low molecular weight heparin on postoperative day 3 to prevent DVT development after radical resection of abdominal tumors
After one year of clinical observations, we found that the administration of low molecular weight heparin on the day of the surgery increases the occurrence of postoperative wound exudate, peritoneal effusion, and intractable fever
Summary
Deep venous thrombosis (DVT) is a serious complication that occurs after major abdominal surgeries. Complications can vary, and severe cases can be fatal due to thrombotic embolism [1]. Existing data show an incidence rate for DVT of 10% to 63% after orthopedic and OPEN ACCESS. IJCM after Radical Resection of Abdominal Tumors general surgery. Postoperative patients with malignant tumors are at high risk for DVT [2]. Treatment after the formation of thrombosis is often not ideal; active preventive treatment is critical. In January 2007, the gastrointestinal surgery center at our institution began standardized administration of low molecular weight dextran and IV salvia for patients with standardized resection of stomach, intestine, hepatobiliary, and pancreatic tumors and subsequent lymph node dissection. Starting in April 2008, we have incorporated low molecular weight heparin. By comparing the three clinical stages of our study, we optimized the drug delivery duration and dosage
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
